tirzepatide loss of exclusivity Generic Zepbound Explained: The Patent Landscape The peptide regulatory landscape in

It belongs to a novel class of agents known as triple agonists, meaning it is designed to target three distinct hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

When performing an intention-to-treat analysis, the HR for MOF was found to be 0.89 [0.781.02] with GLP-1 RAs compared to DPP-4is, although this became significant in the fully adjusted model (HR 0.85 [0.74 0.98])

This delay increases stomach fullness signals and contributes to early post-meal satiety, making individuals eat less at subsequent meals

If you are taking tirzepatide and notice heart palpitations, it is important to assess the situation carefully

Glutamine as A Therapeutic Strategy in Inflammatory Bowel Diseases: A Systematic Review